Collaborators Present Data Supporting Use of Sequenta’s LymphoSIGHT™ Method for Acute Lymphoblastic Leukemia  
12/11/2012 10:15:31 AM

SAN FRANCISCO--(BUSINESS WIRE)--Sequenta, Inc. and their collaborators presented data from four new clinical studies in which the LymphoSIGHT™ method demonstrated superior sensitivity in measuring minimal residual disease (MRD) in bone marrow and peripheral blood from acute lymphoblastic leukemia (ALL) patients. The presentations were made at the 2012 American Society of Hematology (ASH) annual meeting in Atlanta this week.